Information Provided By:
Fly News Breaks for March 27, 2015
OVAS
Mar 27, 2015 | 11:15 EDT
Oppenheimer said earlier today that while it didn't attend the Society of Reproductive Investigation, it heard there was pushback from academics on the validity of the AUGMENT efficacy data. Opco points out, however, that the data "were never going to be as rigorous as that from trial data, so pushback was inevitable." After speaking to a consultant as well as OvaScience management, the firm believes the data are promising for AUGMENT. It keeps an Outperform rating on OvaScience with a $60 price target. Shares are down 9%, or $4.34, to $43.95 in morning trading.
News For OVAS From the Last 2 Days
There are no results for your query OVAS